JalanRSeeryPTaylor-RobinsonSD. Pathogenesis and treatment of chronic hepatic encephalopathy. Aliment Pharm Ther1996; 10:681–97.
2.
MousseauDDButterworthRF. Current theories on the pathogenesis of hepatic encephalopathy. Proc Soc Exp Biol Med1994; 206:329–44.
3.
FischerJEBalsessariniRJ. False neurotransmitters and hepatic failure. Lancet1971; ii:75–80.
4.
FischerJEYoshimuraNJamesJH. Plasma amino acids in patients with hepatic encephalopathy: effects of amino acid infusions. Am J Surg1974; 127:407.
5.
MorganM. Noninvasive neuroinvestigation in liver disease. Semin Liver Dis1996; 16:293–313.
6.
ButterworthRF. The neurobiology of hepatic encephalopathy. Semin Liver Dis1996; 16:235–43.
7.
KulisevskyJPulolJBalanzoJ. Pallidal hyperintensity on magnetic resonance imaging in cirrhotic patients: clinical correlations. Hepatology1992; 6:1382–8.
ZeegenRDrinkwaterJEDawsonAM. Method for measuring cerebral dysfunction in patients with liver disease. Br Med J1970; 2:633–6.
10.
DaviesMGRowanMJFeelyJ. Psychometrics in assessing hepatic encephalopathy - a brief review. Irish J Psych Med1991; 8:144–6.
11.
SchomerusHHamsterWBlunckH. Latent portasystemic encephalopathy: nature of cerebral functional defects and their effect on fitness to drive. Dig Dis Sci1981; 26:622–30.
12.
SrivastavaAMehtaRRothkeSP. Fitness to drive in patients with cirrhosis and portal-systemic shunting: a pilot study evaluating driving performance. J Hepatology1994; 21:1023–8.
13.
SherlockSSummerskillWHJWhiteLP. Portal-systemic encephalopathy: neurological complications of liver disease. Lancet1954: ii:453.
14.
UribeMMarquezAGarcia RamosG. Treatment of chronic portal-systemic encephalopathy with vegetable and animal protein diets: a controlled crossover study. Dig Dis Sci1982; 27:110–916.
15.
FabbriAMagriniNBianchiG. Overview of randomised clinical trials of oral branched-chain amino acid treatment in chronic hepatic encephalopathy. JPEN J Parenter Enteral Nutr1996; 20:159–64.
16.
BircherJMullerJGuggenheimP. Treatment of chronic portal-systemic encephalopathy with lactulose. Lancet1966; i:890–3.
17.
MorganMYHawleyKE. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind randomised trial. Hepatology1987; 7:127–884.
18.
DawsonAMMcLarenJSherlockS. Neomycin in the treatment of hepatic coma. Lancet1957; ii:12–63.
19.
FerenciPHernethASteindlP. Newer approaches to therapy of hepatic encephalopathy. Semin Liver Dis1996; 16:827–32.
20.
SushmaSDasarathySTandenRK. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomised trial. Hepatology1992; 16:13844.
21.
KircheisGNiliusRHeldC. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology1997; 25:1351–60.
22.
JalanREltonRARedheadDN. Analysis of prognostic variables in the prediction of mortality, variceal rebleeding and encephalopathy following transjugular intrahepatic portosystemic stent-shunt for variceal haemorrhage. J Hepatol1995; 23:123–8.
23.
Pomier-LayrarguesG. TIPS and hepatic encephalopathy. Semin Liver Dis1996; 16:315–20.
